Brian Fitzgerald Lasonde, PA
Physician Assistant · Fremont
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
- Since medical school
- 7 years
- Graduated 2019
Offices
2 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Brian Fitzgerald Lasonde’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence G57414 · Cancelled
Licence status: Cancelled · since 1986 · University of California, Irvine College of Medicine.
License has been voluntarily canceled, or the license has been expired for at least five years and has not been renewed. No practice is permitted.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Original Medicare doctor bills
$765,552
Medicare paid this office $765,552 for 290 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, pembrolizumab, 1 mg | 11 | $197,198 | None |
| Injection, denosumab, 1 mg | 24 | $33,812 | None |
| Long return visit (40+ min) | 86 | $16,738 | $143 |
| Administration of chemotherapy into vein, 1 hour or less | 49 | $11,183 | $119 |
| Return visit (30+ min) | 57 | $6,716 | $99 |
See all 20 services
| Injection, pembrolizumab, 1 mg | 11 | $197,198 | None |
| Injection, denosumab, 1 mg | 24 | $33,812 | None |
| Long return visit (40+ min) | 86 | $16,738 | $143 |
| Administration of chemotherapy into vein, 1 hour or less | 49 | $11,183 | $119 |
| Return visit (30+ min) | 57 | $6,716 | $99 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 53 | $4,159 | $57 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 14 | $2,489 | $65 |
| New patient visit (60+ min) | 14 | $2,105 | $150 |
| Short return visit (20+ min) | 26 | $2,028 | $70 |
| Injection of drug or substance under skin or into muscle | 54 | $786 | $12 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 11 | $691 | $18 |
| Injection of drug or substance into vein | 17 | $627 | $33 |
| Injection of additional new drug or substance into vein | 19 | $530 | $14 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 34 | $517 | $13 |
| Administration of chemotherapy into vein, each additional hour | 13 | $512 | $24 |
| Injection, zoledronic acid, 1 mg | 18 | $436 | None |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 12 | $413 | $24 |
| Infusion, normal saline solution, 250 cc | 57 | $45 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 13 | $21 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 11 | $19 | None |
Who their Medicare patients are
290 Original Medicare patients in 2024. Average age 76 · Women 68% · Also on Medicaid 19% · Health risk score 1.69. Above the middle of the specialty; the typical physician assistant clinician is at 1.31.
Conditions among them: High blood pressure 74% · Cancer 41% · Diabetes 40% · Coronary heart disease 31% · Chronic kidney disease 31% · Atrial fibrillation 18% · Depression 18% · Heart failure 16% · COPD 14% · Dementia 7%.
The office billed $2,438,752, Medicare allowed $960,255 and paid $765,552; for 34,890 services of 114 kinds; $711,105 of it was for drugs given in the office and $54,446 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 290 | 34,890 | 76 | 1.69 | $2,438,752 | $765,552 |
| 2023 | 29 | 36 | 66 | 3.49 | $23,809 | $3,485 |
| 2022 | 61 | 88 | 74 | 2.60 | $33,399 | $8,620 |
| 2021 | 45 | 52 | 75 | 2.17 | $29,259 | $5,166 |
| 2020 | 13 | 18 | 70 | 2.04 | $7,236 | $1,126 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 1 service
| Long return visit (40+ min) | 14 | $1,695 | $106 |
2022: 2 services
| Long return visit (40+ min) | 44 | $6,381 | $112 |
| Return visit (30+ min) | 12 | $1,084 | $77 |
2021: 2 services
| Long return visit (40+ min) | 21 | $2,679 | $122 |
| Extended patient service without direct patient contact, first hour | 25 | $2,178 | $87 |
Drugs they prescribed that Part D paid
$2,231,900
Pharmacies billed $2,231,900 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
203 generic and 136 brand-name prescriptions · $2,231,900 in drug cost · 11 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Imbruvica | 17 | $276,937 | $16,290 |
| Lenalidomide | 26 | $272,965 | $10,499 |
| Jakafi | 13 | $238,744 | $18,365 |
| Revlimid | 15 | $216,513 | $14,434 |
| Tagrisso | 12 | $209,859 | $17,488 |
See all 9 drugs
| Imbruvica | 17 | $276,937 | $16,290 |
| Lenalidomide | 26 | $272,965 | $10,499 |
| Jakafi | 13 | $238,744 | $18,365 |
| Revlimid | 15 | $216,513 | $14,434 |
| Tagrisso | 12 | $209,859 | $17,488 |
| Xtandi | 15 | $202,262 | $13,484 |
| Dexamethasone | 25 | $413 | $17 |
| Ondansetron | 15 | $219 | $15 |
| Prednisone | 21 | $121 | $6 |
Year by year
| 2024 | 339 | 96 | None | 40% | $2,231,900 |
| 2023 | 51 | 21 | None | None | $3,947 |
| 2022 | 488 | 91 | 9% (45) | None | $140,562 |
| 2021 | 324 | 77 | 12% (38) | 14% | $123,322 |
| 2020 | 176 | 59 | 7% (13) | 11% | $10,280 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2022: 12 drugs
| Gabapentin | 29 | $2,083 | $72 |
| Morphine Sulfate | 13 | $1,312 | $101 |
| Ondansetron | 44 | $1,179 | $27 |
| Levothyroxine | 79 | $1,019 | $13 |
| Bicalutamide | 15 | $524 | $35 |
| Oxycodone | 11 | $377 | $34 |
| Omeprazole | 21 | $265 | $13 |
| Dexamethasone | 16 | $246 | $15 |
| Prochlorperazine Maleate | 12 | $177 | $15 |
| Chlorhexidine Gluconate | 11 | $164 | $15 |
| Prednisone | 13 | $81 | $6 |
| Lorazepam | 12 | $63 | $5 |
2021: 9 drugs
| Gabapentin | 20 | $1,657 | $83 |
| Morphine Sulfate | 12 | $871 | $73 |
| Levothyroxine | 46 | $675 | $15 |
| Ondansetron | 24 | $448 | $19 |
| Omeprazole | 18 | $340 | $19 |
| Dexamethasone | 16 | $244 | $15 |
| Prochlorperazine Maleate | 13 | $169 | $13 |
| Lidocaine Hcl Viscous | 12 | $140 | $12 |
| Ibuprofen | 12 | $68 | $6 |
2020: 2 drugs
| Levothyroxine | 43 | $591 | $14 |
| Ondansetron | 15 | $313 | $21 |
Money from drug and device companies
$119 in 2025
| 2025 | 5 | 5 | None | $119 |
| 2024 | 7 | 8 | None | $220 |
| 2023 | 1 | 1 | None | $68 |
| 2022 | 1 | 1 | None | $19 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Agios Pharmaceuticals | Pyrukynd | $28 | 1 payment
|
| Caris MPI | Mi Cancer Seek | $25 | 1 payment
|
| Genzyme | Sarclisa | $23 | 1 payment
|
| Janssen Biotech | Rybrevant | $23 | 1 payment
|
| Novocure | Optune Lua (Novottf-200t) | $19 | 1 payment
|
See all 5 published payments
| Caris MPI | Meals · 2025-12-03 | Mi Cancer Seek | $25 |
| Agios Pharmaceuticals | Meals · 2025-05-30 | Pyrukynd | $28 |
| Novocure | Meals · 2025-03-07 | Optune Lua (Novottf-200t) | $19 |
| Janssen Biotech | Meals · 2025-02-26 | Rybrevant | $23 |
| Genzyme | Meals · 2025-01-22 | Sarclisa | $23 |
See earlier years (2024, 2023, 2022)
2024: $220
| AstraZeneca Pharmaceuticals LP | Enhertu | $57 | 2 payments
|
| Merck Sharp & Dohme | Keytruda | $34 | 1 payment
|
| Novartis Pharmaceuticals | Mekinist | $31 | 1 payment
|
| Teleflex | Arrow | $29 | 1 payment
|
| Adaptive Biotechnologies | Clonoseq | $28 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $21 | 1 payment
|
| Array Biopharma | Xalkori | $20 | 1 payment
|
2023: $68
| Myriad Genetic Laboratories | Precisetumor | $68 | 1 payment
|
2022: $19
| Eisai | Lenvima | $19 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1417590092
- Licence
- CA 57414California G57414: Cancelled
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Physician assistant (363A00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2019-10-25
- NPI last updated
- 2023-03-30
- NPI record certified
- 2023-03-30
This is when the NPI record was last certified, not a medical board exam.